吉西他滨联合顺铂与多西他赛联合顺铂在晚期三阴乳腺癌化疗中的对比研究(1)
[摘要] 目的 探讨吉西他滨联合顺铂方案(gemcitabine & cis-platinum，GP方案)与多西他赛联合顺铂方案(docetaxel & cis-platinum，DP方案)在治疗晚期三阴乳腺癌(triple negative breast cancer，TNBC)的近期疗效和不良反应。 方法 采用前瞻性随机对照的临床研究设计，将38例经病理及免疫组化确诊的三阴乳腺癌患者分为GP方案组和DP方案组，观察其近期有效率(response rate，RR)、疾病控制率(disease control rate，DCR)、疾病进展时间(time to progression，TTP)和不良反应。 结果 GP方案组中，完全缓解(complete remission，CR)1例，部分缓解(partial remission，PR)7例，疾病稳定(stable disease，SD)7例，疾病进展(progressive disease，PD)4例，RR为42.1%(8/19)，DCR为78.9%(15/19)；TTP(5.4±0.5)个月。DP方案组中CR 0例，PR 7例，SD 8例，PD 4例，RR为36.8%(7/19)，DCR为78.9%(15/19)；TTP(5.2±0.3)个月。两组的主要不良反应为消化道反应、骨髓抑制。GP方案组血小板减少发生率高于DP方案组(P<0.05)。 结论 GP方案和DP方案治疗晚期TNBC疗效确切，不良反应均可耐受。
[关键词] 三阴乳腺癌；抗肿瘤联合化疗方案；顺铂；吉西他滨；多西他赛
[中图分类号] R737.9 [文献标识码] B [文章编号] 1673-9701(2016)17-0067-03
Clinical trial of cisplatin plus gemcitabine versus cisplatin plus docetaxel for advanced triple-negative breasr cancer
ZHAN Ying TONG Yuanhe CHEN Zhiyong LU Cuiping
Cancer Center， the First Hospital of Longyan Affiliated to Fujian Medical University， Longyan 364000， China
[Abstract] Objective To prospectively evaluate the efficacy and toxicity of cisplatin plus gemcitabine(GP regimen) versus cisplatin plus docetaxel(DP regimen) in treatment of advanced triple-negative breast cancer(TNBC). Methods A prospective randomized controlled clinical study was designed， 38 patients confirmed TNBC patients by pathology and immunohistochemistry were divided into GP regimen group and DP regimen group. The response rate(RR)， disease control rate (DCR)， median time to tumor progression (TTP) and side effects were observed. Results Among the 19 case of GP regimen group， 1 patient had CR， 7 patients had PR， 7 patients had SD and 4 patients had PD. The RR and DCR were 42.1% (8/19) and 78.9%(15/19)， the TTP was (5.4±0.5) months. Among the 19 case of DP regimen group， no patient had CR， 7 patients had PR， 8 patients had SD and 4 patients had PD. The RR and DCR were 36.8%(7/19) and 78.9% (15/19). The TTP was (5.2±0.3) months. The main side effects of the two groups included hematologic toxicities， digestive tract reaction and myelosuppression. The incidence of thrombocytopenia in the GP regimen group was significantly higher than that in the DP regimen group(P<0.05). Conclusion Our findings demonstrate that the DP and GP regimens have similar efficacy as treatment for advanced TNBC. The major toxicities of the two regimens are well tolerable.
[Key words] TNBC； Antineoplastic combined chemotherapy protocol； Cisplatin； Gemcitabine； Docetaxel, 百拇医药(詹颖 童远和 陈志勇 卢翠萍)
[关键词] 三阴乳腺癌；抗肿瘤联合化疗方案；顺铂；吉西他滨；多西他赛
[中图分类号] R737.9 [文献标识码] B [文章编号] 1673-9701(2016)17-0067-03
Clinical trial of cisplatin plus gemcitabine versus cisplatin plus docetaxel for advanced triple-negative breasr cancer
ZHAN Ying TONG Yuanhe CHEN Zhiyong LU Cuiping
Cancer Center， the First Hospital of Longyan Affiliated to Fujian Medical University， Longyan 364000， China
[Abstract] Objective To prospectively evaluate the efficacy and toxicity of cisplatin plus gemcitabine(GP regimen) versus cisplatin plus docetaxel(DP regimen) in treatment of advanced triple-negative breast cancer(TNBC). Methods A prospective randomized controlled clinical study was designed， 38 patients confirmed TNBC patients by pathology and immunohistochemistry were divided into GP regimen group and DP regimen group. The response rate(RR)， disease control rate (DCR)， median time to tumor progression (TTP) and side effects were observed. Results Among the 19 case of GP regimen group， 1 patient had CR， 7 patients had PR， 7 patients had SD and 4 patients had PD. The RR and DCR were 42.1% (8/19) and 78.9%(15/19)， the TTP was (5.4±0.5) months. Among the 19 case of DP regimen group， no patient had CR， 7 patients had PR， 8 patients had SD and 4 patients had PD. The RR and DCR were 36.8%(7/19) and 78.9% (15/19). The TTP was (5.2±0.3) months. The main side effects of the two groups included hematologic toxicities， digestive tract reaction and myelosuppression. The incidence of thrombocytopenia in the GP regimen group was significantly higher than that in the DP regimen group(P<0.05). Conclusion Our findings demonstrate that the DP and GP regimens have similar efficacy as treatment for advanced TNBC. The major toxicities of the two regimens are well tolerable.
[Key words] TNBC； Antineoplastic combined chemotherapy protocol； Cisplatin； Gemcitabine； Docetaxel, 百拇医药(詹颖 童远和 陈志勇 卢翠萍)